Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238027 | 0.92 | PKM (0.51) | PKML3MBTL1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL30722828 | 0.89 | PKM (0.51) | PKML3MBTL1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL3222691 | 0.89 | PKM (0.51) | PKML3MBTL1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL20067126 | 0.86 | L3MBTL1 (0.51) | PKML3MBTL1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL19904763 | 0.86 | PKM (0.49) | PKML3MBTL1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL3224957 | 0.85 | L3MBTL1 (0.52) | PKML3MBTL1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL30259759 | 0.80 | L3MBTL1 (0.48) | PKML3MBTL1LMNASMN1; SMN2CYP3A4 | |
| SCHEMBL3222660 | 0.80 | LMNA (0.51) | PKML3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL32660807 | 0.80 | LMNA (0.51) | PKML3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL7038982 | 0.80 | LMNA (0.58) | PKML3MBTL1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097428-B1 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | MGP BIOTECHNOLOGIES INC (US) | 2018-02-28 | — | — | EP | disclosed |